Figure 4.
Caspase 3 was activated in head and neck squamous cell carcinoma cells treated with withaferin A (1). HNSCC cells was treated with different concentrations of 1 for 24 h. Levels of pro-caspase 3 (inactive form) was examined with the antibody against uncleaved caspase 3. In addition, activation of caspase 3 was examined with levels of the uncleaved and cleaved caspase 3 substrate, PARP. Compound 1 induced caspase 3 activation in all HNSCC cell lines in a concentration-dependent manner.